Skip to main content
NewslettersWatchlist

Innoviva Inc(INVA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low15.72
Day High15.88
Open:15.88
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Chart of the Day: Innoviva - Individual Investor Favorite
PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR Newswire
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Business Wire
Innoviva Announces Retirement of Board Chairman
Barchart
Markets Today: Stock Index Futures Climb as China’s Economy Strengthens
Business Wire
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
Business Wire
Innoviva Stock Trading Halted Today
Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
PR Newswire
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
MarketBeat
Four Undervalued Healthcare Stocks for 2023
Business Wire
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
Business Wire
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Business Wire
La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
Business Wire
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Business Wire
Innoviva Completes Acquisition of La Jolla Pharmaceutical
Business Wire
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Business Wire
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
Globe Newswire
Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million
PR Newswire
SHAREHOLDER ALERT: Weiss Law Investigates La Jolla Pharmaceutical Company
Business Wire
LA JOLLA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of La Jolla Pharmaceutical Company - LJPC
Business Wire
Innoviva Completes Acquisition of Entasis Therapeutics
Business Wire
Innoviva to Acquire La Jolla Pharmaceutical Company
Business Wire
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
PR Newswire
SHAREHOLDER ALERT: Weiss Law Reminds BHVN, SWCH, ETTX, and TVTY Shareholders About Its Ongoing Investigations
PR Newswire
SHAREHOLDER ALERT: Weiss Law Reminds ETTX, TVTY, MANT, and RTLR Shareholders About Its Ongoing Investigations
Business Wire
Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX
Business Wire
ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX
Business Wire
Innoviva to Acquire Entasis Therapeutics
Business Wire
Innoviva Reports First Quarter 2022 Financial Results
Motley Fool
1 Healthcare Stock That Could Fly Higher After a Strong Q4
Business Wire
Innoviva Reports Fourth Quarter 2021 Financial Results

Profile

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.